Craig-Hallum Maintains Buy on Myriad Genetics, Raises Price Target to $8

Craig-Hallum analyst John Wilkin has maintained a Buy rating on Myriad Genetics (NASDAQ: MYGN) and increased the price target from $4 to $8.